Incyte Genomics Inc

INCYNASDAQ • USD
117.74 USD
↘ 1.35 (1.13%)🟢PRE MARKET (AS OF 04:08 AM EST)
🟢Market: OPEN

INCY is currently priced at $117.74. Technicals currently rate "Sell" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score and a bullish Golden Cross on the moving averages. On the valuation front, INCY trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.

Technical & fundamental data as of Nov 18, 2026.

Open?$117.07
High?$117.74
Low?$117.07
Prev. Close?$119.09
Volume?10
Avg. Volume?1.8M
VWAP?$117.07
Rel. Volume?0.00x
Bid / Ask
Bid?$112.57 × 100
Ask?$124.41 × 100
Spread?$11.84
Midpoint?$118.49
Valuation & Ratios
Market Cap?24.0B
Shares Out?203.8M
Float?168.9M
Float %?83.4%
P/E Ratio?59.52
P/B Ratio?4.26
EPS?$1.98
Dividend?0.00%
Ex-Dividend?N/A
RelatedABBV
News
Profile
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
Employees
2.8K
Market Cap
24.3B
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Listed
1993-11-03
Address
1801 AUGUSTINE CUT-OFF
WILMINGTON, DE 19803
Phone: (302) 498-6700
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
100
Momentum?
35
Short Sent.?
64
Piotroski F-Score?4/9Mixed
Altman Z-Score?19.73Safe
Confidence?64%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?6.30%Elevated
Short Interest?10.6M
Days to Cover?5.6
Free Float168.9M
Avg Daily Volume1.9M
Settlement Date2026-10-30
Financial Health
Current Ratio?3.84Strong
Quick Ratio?3.75Strong
Cash Ratio?2.28Strong
Debt/Equity?0.01Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
Peers
50
S&P
9
59.5PRICEY▾
P/B?
S&P
42
4.26FAIR▾
P/S?
Peers
100
S&P
38
3.99FAIR▾
P/FCF?
Peers
50
S&P
21
35.1PRICEY▾
EV/EBITDA?
Peers
50
S&P
15
25.9HIGH▾
EV/Sales?
Peers
100
S&P
54
3.46FAIR▾
Returns & Efficiency
ROE?
S&P
23
7.1%FAIR▾
ROA?
Peers
50
S&P
50
5.5%FAIR▾
Cash Flow & Enterprise
FCF?$684.9M
Enterprise Value?$20.8B
Fundamentals ratios updated end of day